Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse

Diabetes

Volumn 51, Issue 7, 2002, Pages 2082-2089

  Hofmann, Susanna M ^a   Dong, Heng Jiang ^a   Li, Zhu ^a   Cai, Weijing ^a   Altomonte, Jennifer ^a   Thung, Swan N ^a   Zeng, Feng ^a   Fisher, Edward A ^a   Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; INSULIN; METHYLGLYOXAL;

ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; GLUCOSE TRANSPORT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; MOUSE; NONHUMAN; NUTRIENT; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0036300606     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.7.2082     Document Type: Article

References (51)

1. Preventing diabetes: Applying pathophysiological and epidemiological evidence
2. Deconstructing type 2 diabetes
3. The metabolic syndrome X
4. Nutritionally induced insulin resistance and receptor defect leading to beta-cell failure in animal models
5. Effects of a traditional lifestyle on obesity in Pima Indians
6. Nutrient modulation of cellular insulin action
7. Diet composition and insulin action in animal models
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
9. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
10. Advanced glycation end-products: A review
11. Nutritional and toxicological aspects of the Maillard browning reaction in foods
12. Intervening in atherogenesis: Lessons from diabetes
13. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
14. Dietary glycotoxins: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration
15. New biomarkers of Maillard reaction damage to proteins
16. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
17. Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells: The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes
18. The advanced glycation end product, N epsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions
19. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications
20. Reactive carbonyl compounds related uremic toxicity ("carbonyl stress")
21. Lipid advanced glycosylation: Pathway for lipid oxidation in vivo
22. Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation
23. Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine
24. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through the glycation reaction
25. Negative consequences of glycation
26. AGE-restricted diet decreases incidence of diabetes and prolongs survival in NOD mice
27. Suppression of atherosclerotic lesions by dietary restriction of advanced glycation end products (AGEs) in diabetic, apolipoprotein E-deficient C57BL/6J mice
28. Animal models of diabetes
29. Standardizing the immunological measurement of advanced glycation endproducts using normal human serum
30. Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity
31. N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction
32. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins
33. Methylglyoxal modification of protein: Chemical and immunochemical characterization of methylglyoxal-arginine adducts
34. Genetic heterogeneity of lipoproteins in inbred strains of mice: Analysis by gel-permeation chromatography
35. The db/db mouse, a model for diabetic dyslipidemia: Molecular characterization and effects of Western diet feeding
36. Restriction of AGE content of food, without lowering protein intake prevents diabetic nephropathy (DN) in mice
37. Hyperinsulinemia in pre-weaning diabetes (db) mice
38. Diagnosing insulin resistance in the general population
39. Alteration of islet cell populations in spontaneously diabetic mice
40. Obesity and insulin resistance
41. Hepatic metabolism of genetically diabetic (db/db) mice. I. Carbohydrate metabolism
42. Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice
43. Hyperglucagonemia of the isolated perfused pancreas of diabetic mice (db-db)
44. The possible role of age-related increase in the plasma glucagon/insulin ratio in the enhanced hepatic gluconeogenesis and hyperglycemia in genetically diabetic (C57BL/KsJ-db/db) mice
45. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
46. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice: Possible role of leptin in stimulation of HDL turnover
47. Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats
48. Lipoprotein physiology in nondiabetic and diabetic states: Relationship to atherogenesis
49. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
50. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes